THE ARISING · Markets & Strategy
Atrogi's Oral Muscle Drug Linked to 13% Power Gain in Small Study
A pill that could add muscle while taking off fat would stand apart in a weight-loss field where, by widely reported background not drawn from this source, many drugs tend to cost people lean mass. Atrogi says it now has early human data pointing that way. The study was small, open-label and had no control group, and we could not confirm whether it has been peer-reviewed, so the claim is far from proven. The drug was associated with the gain, which is not the same as causing it.
This article is based on PharmaTimes' report of the study. The paper itself was not retrieved or reviewed, and nothing here has been checked against it.
According to PharmaTimes' report, Atrogi announced positive human data for ATR258. The company describes it as a first-in-class oral GRK2-biased β2-adrenergic modulator, designed to improve muscle function and body composition.
PharmaTimes reports that the study ran for 8 weeks in 13 overweight or obese adults. It was investigator-initiated, open-label and single-arm, so there was no placebo group. It tested three ascending dose levels. Professor Morten Hostrup led it.
According to the report, the therapy was well tolerated and associated with an approximately 13% mean improvement in lower-extremity muscle power. Mean fat mass fell by 1.1 kg and lean mass rose by 0.8 kg. PharmaTimes says the changes in fat and lean mass were statistically significant.
On positioning, the company is pitching a differentiated profile: fat loss alongside more lean mass and better muscle function. Chief Scientific Officer and founder Tore Bengtsson said the data "give us important confidence that our approach is translating." He also said the mechanism warrants investigation in sarcopenia and in rare diseases marked by major muscle loss and weakness.
The report says the results build on a 2025 Cell publication. That paper described the GRK2-biased signalling approach and first-in-human safety data from a 69-subject phase 1 trial. PharmaTimes says the new results give first human proof of mechanism and support a phase 2 trial planned for 2027. That proof-of-mechanism framing comes from the company announcement. Hostrup, the principal investigator, also commented, saying the magnitude of the signal in lower-extremity power struck him most. CEO Paul Little called Atrogi "a phase 2-ready biotech."
For strategy, the case rests on a gap the company is aiming at: muscle-sparing options in metabolic disease and possible uses in muscle-wasting conditions. Several points are not in the coverage. These include how the drug compares with existing treatments, how regulators would view muscle power as an endpoint, and what a phase 2 trial would cost. Those are open questions, not findings.
The caution is plain, and this is where the argument is weakest. With 13 people and no control group, the study cannot separate the drug's effect from other influences. The coverage also gives no data on how long any gains last. The company's own statements make up much of the report.
What to watch next
The design and endpoints of the phase 2 trial planned for 2027, and whether a placebo-controlled study confirms the muscle power signal.
Major Hospitals Open Longevity Clinics, and STAT Asks Whether They Work PPIC Projects California's 65-Plus Labor Force Will Reach 1.8 Million by 2040 FDA Approves Viatris' Ryzumvi Eye Drops for Presbyopia in Adults Wyden Seeks Input on Medicare or Medicaid Universal Home Care Benefit Atrogi's Oral Muscle Drug Linked to 13% Power Gain in Small Study Over 90% of US Nursing Homes Staff Below Acuity-Based Expected Level, LTCCC Says